The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1146 articles
A comprehensive analysis of recent data shows that stopping GLP-1 medications like Ozempic and Wegovy often leads to weight regain and a return of cardiometabolic risk markers. Here is what you need to know about long-term outcomes and maintenance strategies.
Dr. Reddy's Laboratories has achieved a significant milestone by becoming the first company to receive market authorization from Health Canada for its generic semaglutide injection. This development promises to increase access to a crucial treatment option for Canadians.
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
Recent preclinical research suggests that inconsistent use of GLP-1 medications like Ozempic and Wegovy may diminish their effectiveness over time. Discover the science behind adherence and how to optimize your therapy.
The rise of GLP-1 medications has led to an unexpected surge in hot sauce sales. Explore the science behind altered taste perception and how it's influencing consumer choices.
GLP-1 therapies are revolutionizing weight loss, but their widespread adoption raises critical questions about diagnostic preparedness. This article explores the growing need for robust testing frameworks to ensure the safe and effective use of these powerful medications.
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
